Data to be presented at the conferences will provide insights into the transition from empiric to rationally selected and personalized therapy utilizing the platform. The iGXT Platform is currently being employed in studies of Non-Small Cell Lung Cancer (NSCLC) involving Epidermal Growth Factor Receptor (EGFR)-directed therapies, mutation-specific GEMM and PDX models, and in conjunction with genome-wide assessment of altered gene expression and other molecular changes, pre-and post-therapy.
Future plans are for the platform to expand into brain cancers, ovarian cancer, prostate cancer and melanoma.
Specific studies are currently being conducted in collaboration with pharmaceutical companies and others in the biomedical research community. Organizations are encouraged to inquire about access to the platform for specific studies, and for models and materials that are available through the Center for Advanced Preclinical Research and Jackson Laboratory programs.
"There is an urgent need for more predictive models of human cancer for drug discovery," said Chuck Hewett, Ph.D., Executive Vice President and COO of The Jackson Laboratory. "Unfortunately, nine out of 10 cancer drugs entering preclinical testing fail. This comes at great cost to the pharmaceutical industry and to patients. The integrated approach we have with CAPR and UC Davis targets these issues directly."
David Hoekzema, Vice President for Business Development at SAIC-Frederick, said, "Knowledge of the genetic basis of human cancers can be combined with advanced genetic engineering techniques to produce lab animals that mimic the diseases in humans more accurately than traditional experimental mouse models. By integrating CAPR's expertise in this area with the unique capabilities of JAX, and into the clinical environment of UC Davis
|Contact: Joyce Peterson|